Thiamine as a Renal Protective Agent in Septic Shock Read more about Thiamine as a Renal Protective Agent in Septic Shock
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Read more about Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies Read more about Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Read more about A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Read more about A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Read more about Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 Read more about ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants. Read more about A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy Read more about Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) Read more about Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)